Enhanced Anti-Nociception by Novel Dual Antagonists for 5-HT2AR and mGluR5 in Preclinical Models of Pain
Biomolecules · 15.10.2025 · 15 (10) · 1456
DOI: 10.3390/biom15101456 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, online erschienen am 15.10.2025. Verfasst von Daekyu Choi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research Institute and Drug Development, Vivozon, Inc., Yongin-si 16914, Gyeonggi-do, Republic of Korea. Hauptthemen laut MEDLINE: Receptor, Metabotropic Glutamate 5, Neuralgia, Serotonin 5-HT2 Receptor Antagonists, Receptor, Serotonin, 5-HT2A. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Extensive research has focused on developing anti-nociceptive therapy by targeting specific molecular pathways. Among these, the serotonin 2A receptor (5-HT2AR) and metabotropic glutamate receptor 5 (mGluR5) are recognized as key mediators of neuropathic pain. However, the therapeutic potential of their simultaneous inhibition remains largely unexplored. In this study, we evaluated the efficacy of dual antagonism of 5-HT2AR and mGluR5 using spinal nerve ligation (SNL) and formalin-induced pain models in male Sprague–Dawley rats. Co-administration of selective antagonists significantly enhanced anti-allodynic and anti-nociceptive effects, as evidenced by increased withdrawal thresholds and reduced pain-related behaviors compared to monotherapy. The analgesic efficacy of dual antagonism was comparable to that of gabapentin and morphine. Additionally, novel small molecules designed to concurrently inhibit 5-HT2AR and mGluR5 exerted dose-dependent anti-nociceptive effects by suppressing excitatory postsynaptic responses and inhibiting the phosphorylation of ERK and AKT signaling molecules. Importantly, unlike morphine, repeated administration of the dual antagonist maintained anti-allodynic efficacy with a low potential of abuse. These findings may indicate the promise of simultaneous 5-HT2AR and mGluR5 antagonism as a novel and potentially safer strategy for managing chronic neuropathic pain.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Research Institute and Drug Development, Vivozon, Inc., Yongin-si 16914, Gyeonggi-do, Republic of Korea.
- Department of Pharmacology, School of Pharmacy, Sungkyunkwan University, Suwon 16419, Gyeonggi-do, Republic of Korea.
ORCID-Profile: Daekyu Choi, Hyun Jin Heo, Choon-Gon Jang, Hanmi Lee
Förderung
- National Research Foundation of Korea
Zitieren
APA
Choi, D., Heo, H. J., Shin, H., Im, J., Lee, G., Kim, A. H., Hur, K. H., Nho, Y., Jang, C. G., & Lee, H. (2025). Enhanced Anti-Nociception by Novel Dual Antagonists for 5-HT2AR and mGluR5 in Preclinical Models of Pain. Biomolecules, 15(10), 1456. https://doi.org/10.3390/biom15101456
Vancouver
Choi D, Heo HJ, Shin H, Im J, Lee G, Kim AH, et al. Enhanced Anti-Nociception by Novel Dual Antagonists for 5-HT2AR and mGluR5 in Preclinical Models of Pain. Biomolecules. 2025;15(10):1456. doi:10.3390/biom15101456
BibTeX
@article{Choi2025,
author = {Choi, Daekyu and Heo, Hyun Jin and Shin, Haeyoung and Im, Jayzoon and Lee, Geonho and Kim, Ah Hyun and Hur, Kwang-Hyun and Nho, Yoonmi and Jang, Choon-Gon and Lee, Hanmi},
title = {Enhanced Anti-Nociception by Novel Dual Antagonists for 5-HT2AR and mGluR5 in Preclinical Models of Pain},
journal = {Biomolecules},
year = {2025},
volume = {15},
number = {10},
pages = {1456},
doi = {10.3390/biom15101456}
}
EUVIMED